Prions: A model of conformational disease?

Pathologie Biologie

Volumn 62, Issue 2, 2014, Pages 96-99

  Morinet, F ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Conformational disease; Degenerative disease; Folding; Prions; sheet

Indexed keywords

ASTEMIZOLE; PRION PROTEIN; TACROLIMUS; AMYLOID; PRION;

ANTIVIRAL ACTIVITY; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; CONFORMATIONAL TRANSITION; CREUTZFELDT JAKOB DISEASE; FATAL FAMILIAL INSOMNIA; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; INCIDENCE; NONHUMAN; PRION; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN UNFOLDING; VIRAL CLEARANCE; ANIMAL; CHEMISTRY; METABOLISM; PRION DISEASES; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEINOSIS; PROTEOSTASIS DEFICIENCY; STRUCTURE ACTIVITY RELATION; TRANSMISSION; VETERINARY;

AMYLOID; ANIMALS; HUMANS; PRION DISEASES; PRIONS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEOSTASIS DEFICIENCIES; PRPC PROTEINS; PRPSC PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898430929     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2014.02.003     Document Type: Article

References (36)

1. Morinet F., Courouce A.M., Galibert F., Perol Y. The use of labeled fusion protein for detection of B19 parvovirus IgM antibodies by an immunocapture test. J Virol Methods 1991, 32:21-30.
2. Carrell R.W., Lomas D.A. Conformational disease. Lancet 1997, 350:134-138.
3. Holmes D.L., Lancaster A.K., Lindquist S., Halfmann R. Heritable remodeling of yeast multicellularity by an environmentally responsive prion. Cell 2013, 153:153-165.
4. Zerr I. Human prion diseases: progress in clinical trials. Brain 2013, 136:996-997.
5. Colby D.W., Prusiner S. Prions. Cold Spring Harb Perspect Biol 2011, 3:a006833.
6. Colchester A.C.F., Colchester N.T.H. The origin of bovine spongiform encephalopathy: the human prion disease hypothesis. Lancet 2005, 366:856-861.
7. st century-an acquired human prion disease with very long incubation periods. Lancet 2006, 367:2068-2074.
8. Lindenbaum S. Cannibalism, Kuru and anthropology. Folia Neuropathol 2009, 47:138-144.
9. Editorial Prion diseases remain a mystery. Lancet Infect Dis 2012, 12:897.
10. Prusiner S. A unifying role for prions in neurodegenerative disease. Science 2012, 336:1511-1513.
11. Griffith F. The significance of pneumococcal types. J Hyg (London) 1928, 27:113-159.
12. Avery O.T., MacLeod C.M., Mc Carty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med 1944, 79:137-158.
13. Fink G.R. A transforming principle. Cell 2005, 120:153-154.
14. Villar-Piqué A., Ventura S. Modeling amyloids in bacteria. Microbial Cell Factories 2012, 11:166.
15. Bednarska N.G., Schymkowitz J., Rousseau F., Van Eldere J. Protein aggregation in bacteria: the thin boundary between functionality and toxicity. Microbiology 2013, 159:1795-1806.
16. Rosenzweig R., Moradi S., Zarrine-Afsar A., Glover J.R., Kay L.E. Unraveling the mechanism of protein disaggregation through a ClpB-DnaK interaction. Science 2013, 339:1080-1083.
17. Dill K.A., MacCallum J.L. The protein-folding problem, 50 years on. Science 2012, 338:1042-1046.
18. Edgeworth J.A., Gros N., Alden J., Joiner S., Wadsworth J.D.F., Linehan J., et al. Spontaneous generation of mammalian prions. Proc Natl Acad Sci 2010, 107:14402-14406.
19. Edgeworth J.A., Jackson G., Clarke A.R., Weissmann C., Collinge J. Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces. Proc Natl Acad Sci 2009, 106:3479-3483.
20. Halfmann R., Alberti S., Krishnan R., Lyle N., O'Donnell C.W., King O.D., et al. Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol Cell 2011, 43:72-84.
21. Li j, Browning S., Mahal S., Oelschlegel A.M., Weissmann C. Darwinian evolution of prions in cell culture. Science 2010, 327:869-872.
22. Aguzzi A., Steele A.D. Prion topology and toxicity. Cell 2009, 137:994-996.
23. Chakrabarti S., Hedge R.S. Functional depletion of mahogunin by cytosolically exposed prion protein contributes to neurodegeneration. Cell 2009, 137:1136-1147.
24. Polymenidou M., Cleveland D.W. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 2012, 209:889-893.
25. Reid A.T., Evans A.C. Structural networks in Alzheimer's disease. Europ Neuropsychopharmacol 2013, 23:63-77.
26. Golde T.E., Borchelt D.R., Giasson B.I., Lewis J. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest 2013, 123:1847-1855.
27. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., Dumouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719.
28. Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012, 149:968-977.
29. Prusiner S.B. Prions. Proc Natl Acad Sci 1998, 95:13363-13383. [Nobel Lecture].
30. Hou F., Sun L., Zheng H., Skaug B., Jiang Q.X., Chen Z.J. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011, 146:448-461.
31. Krüttner S., Stepien B., Noordermeer J.N., Mommaas M.A., Mechtler K., Dickson B.J., et al. Drosophila CPEB Orb2A mediates memory independent of Its RNA-binding domain. Neuron 2012, 76:383-395.
32. Halfmann R., Lindquist S. Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science 2010, 330:629-632.
33. de Jong I.G., Haccou P., Kuipers O.P. Bet-hedging or not? A guide to proper classification of microbial survival strategies. Bioessays 2011, 33:215-223.
34. Kurnellas M.P., Adams C.M., Sobel R.A., Steinman L., Rothbard J.B. Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med 2013, 5:179ra42.
35. Roettger Y., Du Y., Bacher M., Zerr I., Dodel R., Bach J.P. Immunotherapy in prion disease. Nat Rev Neurol 2013, 9:98-105.
36. Karapetyan Y.E., Sferrazza G.F., Zhou M., Ottenberg G., Spicer T., Chase P., et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci 2013, 110:7044-7049.